Negotiable: Oxford Nanopore Technologies: We are looking for an individual with expertise in bioinformatics and statistics and in-depth knowledge of the range and limitations of existing bioi San Francisco, California

Notice NOT-OD-22-130 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-22-034 from the NIH Guide for Grants and Contracts. To support studies on the clinical history of three sexually transmitted infections (STIs): syphilis, gonorrhea, and chlamydia. Improved understanding of the human immune response after infection through diagnosis and treatment will provide a much-needed knowledge base to accelerate vaccine and diagnostic development.

Funding Opportunity RFA-RM-22-020 from the NIH Guide for Grants and Contracts. The NIH Directors Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nations research workforce. Individuals from diverse backgrounds, including those from underrepresented groups (see, Notice of NIH's Interest in Diversity, NOT-OD-20-031) are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications are welcome from the full spectrum of eligible institutions in all geographic locations and in all topic areas relevant to the broad mission of NIH, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Directors Transformative Research Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund. Towards the objective of funding the best possible science, the Office of Strategic Coordination and the Center for Scientific Review are piloting a process for initial peer review of applications received in response to this FOA in which the identity of the investigators and institutions are withheld until the last phase of review. Instructions for anonymizing components of the application are given in Section IV and must be carefully followed. A description of the review process is given in Section V.

Funding Opportunity RFA-DA-23-027 from the NIH Guide for Grants and Contracts. oThe purpose of this concept is to invite R25 applications that disseminate analytical and computational methodologies and best practices through educational activities with hands-on research experience.

Notice NOT-OD-22-106 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-107 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-22-071 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code.

Funding Opportunity RFA-CA-22-027 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that aim to understand and address the survivorship needs of individuals living with likely incurable cancers. Specifically, this FOA solicits observational and interventional research to determine the scope of the needs of and develop interventions to improve outcomes for these survivors.

Competitive Salary: F. Hoffmann-La Roche AG: The PositionSenior Backend EngineerLocation: Mississauga or Across CanadaImpact HealthcareRoche Sequencing is not only changing science, but we are ch Ottawa (Region), Ontario (CA)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionPrincipal Backend Software EngineerLocation: Mississauga or Across CanadaImpact HealthcareRoche Sequencing is not only changing science, b Ottawa (Region), Ontario (CA)

Competitive Salary: EMBL: We are looking for a highly motivated Python Software developer to join the Ensembl Production Team. Come and help us design and implement the future Hinxton, Cambridgeshire, England

Competitive Salary: EMBL: We are looking for a proactive and collaborative mid-weight Digital Product Designer to join EMBL’s European Bioinformatics Institute (EMBL-EBI) in ou Hinxton, Cambridgeshire, England

Funding Opportunity PA-22-175 from the NIH Guide for Grants and Contracts. The objective of this NOFO is to notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of research grants (activity codes listed above) that funds are available for competitive revisions to enhance the diversity of the research workforce by recruiting and supporting students, post doctorates, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health services research. This opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project

Notice NOT-HD-22-007 from the NIH Guide for Grants and Contracts

£40000 - £50000 per annum: Hyper Recruitment Solutions (HRS): We are currently looking for a Bioinformatics Scientist - Biostats to join a leading biotech company based in the Cambridgeshire area. As the Bioinformatics Scientist - Biostats... Cambridgeshire

Notice NOT-OD-22-131 from the NIH Guide for Grants and Contracts

from £38,300 subject to skills and experience : The Francis Crick Institute: An exciting opportunity to be part of pioneering biomedical research institute, dedicated to innovation and science, in the laboratory of S.Turajilic London (Central), London (Greater)

£40000 - £50000 per annum: Hyper Recruitment Solutions (HRS): We are currently looking for a Bioinformatic Pipeline Tester to join a leading Biotech company based in the Cambridgeshire area. As the Bioinformatic Pipeline Tester... Cambridgeshire

Preferred/Optional: Dissertation that focused on complex covariance structures, missing data problems, survival analysis, bioinformatics, or another area…
From Marshfield Clinic Health System - Wed, 11 May 2022 07:11:19 GMT - View all Marshfield, WI jobs